Figure 2.

Flow of patients through the study. *, IGF-1 levels decreased by < 10% at week 24 vs baseline (as defined in the protocol) or investigator's judgment of insufficient response; †, patient not able to attend due to mobility issues; §, one patient had two major protocol violations.